Latest Insider Transactions at Biocryst Pharmaceuticals Inc (BCRX)
This section provides a real-time view of insider transactions for Biocryst Pharmaceuticals Inc (BCRX). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of BIOCRYST PHARMACEUTICALS INC to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of BIOCRYST PHARMACEUTICALS INC's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 23
2021
|
Anthony Doyle Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
35,258
+27.34%
|
$423,096
$12.48 P/Share
|
|
Nov 15
2021
|
George B Abercrombie Director |
SELL
Open market or private sale
|
Direct |
5,000
-100.0%
|
$60,000
$12.27 P/Share
|
|
Nov 15
2021
|
George B Abercrombie Director |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+50.0%
|
$15,000
$3.32 P/Share
|
|
Oct 15
2021
|
Nancy J Hutson Director |
SELL
Open market or private sale
|
Direct |
105,000
-61.74%
|
$1,575,000
$15.4 P/Share
|
|
Oct 15
2021
|
Nancy J Hutson Director |
BUY
Exercise of conversion of derivative security
|
Direct |
105,000
+17.0%
|
$315,000
$3.24 P/Share
|
|
Sep 15
2021
|
George B Abercrombie Director |
SELL
Open market or private sale
|
Direct |
5,000
-100.0%
|
$75,000
$15.06 P/Share
|
|
Sep 15
2021
|
George B Abercrombie Director |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+50.0%
|
$10,000
$2.63 P/Share
|
|
Sep 13
2021
|
Kenneth B Lee Jr Director |
SELL
Open market or private sale
|
Direct |
6,000
-19.83%
|
$90,000
$15.35 P/Share
|
|
Sep 13
2021
|
Kenneth B Lee Jr Director |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+33.15%
|
$45,000
$3.22 P/Share
|
|
Sep 10
2021
|
George B Abercrombie Director |
SELL
Open market or private sale
|
Direct |
74,000
-100.0%
|
$1,110,000
$15.09 P/Share
|
|
Sep 10
2021
|
George B Abercrombie Director |
BUY
Exercise of conversion of derivative security
|
Direct |
71,000
+37.8%
|
$142,000
$2.61 P/Share
|
|
Sep 01
2021
|
Jon P Stonehouse President & CEO |
BUY
Bona fide gift
|
Indirect |
10,000
+50.0%
|
-
|
|
Sep 01
2021
|
Jon P Stonehouse President & CEO |
SELL
Bona fide gift
|
Direct |
10,000
-0.64%
|
-
|
|
Aug 31
2021
|
Steve Aselage Director |
BUY
Grant, award, or other acquisition
|
Direct |
314
+0.96%
|
$4,710
$15.92 P/Share
|
|
Aug 31
2021
|
Theresa Heggie Director |
BUY
Grant, award, or other acquisition
|
Direct |
628
+4.07%
|
$9,420
$15.92 P/Share
|
|
Aug 31
2021
|
Robert Alexander Ingram Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,177
+1.5%
|
$17,655
$15.92 P/Share
|
|
Aug 31
2021
|
Alan G Levin Director |
BUY
Grant, award, or other acquisition
|
Direct |
628
+50.0%
|
$9,420
$15.92 P/Share
|
|
Jul 15
2021
|
George B Abercrombie Director |
SELL
Open market or private sale
|
Direct |
5,000
-62.5%
|
$75,000
$15.69 P/Share
|
|
Jul 15
2021
|
George B Abercrombie Director |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+38.46%
|
$10,000
$2.63 P/Share
|
|
Jun 10
2021
|
Nancy J Hutson Director |
SELL
Open market or private sale
|
Direct |
23,333
-26.39%
|
$373,328
$16.86 P/Share
|
|
Jun 10
2021
|
Nancy J Hutson Director |
BUY
Exercise of conversion of derivative security
|
Direct |
23,333
+12.35%
|
$69,999
$3.09 P/Share
|
|
May 28
2021
|
Steve Aselage Director |
BUY
Grant, award, or other acquisition
|
Direct |
634
+1.94%
|
$9,510
$15.77 P/Share
|
|
May 28
2021
|
Theresa Heggie Director |
BUY
Grant, award, or other acquisition
|
Direct |
317
+2.19%
|
$4,755
$15.77 P/Share
|
|
May 28
2021
|
Nancy J Hutson Director |
BUY
Grant, award, or other acquisition
|
Direct |
317
+0.48%
|
$4,755
$15.77 P/Share
|
|
May 28
2021
|
Robert Alexander Ingram Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,188
+1.54%
|
$17,820
$15.77 P/Share
|
|
May 28
2021
|
William P Sheridan Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
91,814
-86.38%
|
$1,377,210
$15.02 P/Share
|
|
May 28
2021
|
William P Sheridan Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
91,814
+27.25%
|
$459,070
$5.26 P/Share
|
|
May 27
2021
|
William P Sheridan Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
71,759
-83.21%
|
$1,076,385
$15.0 P/Share
|
|
May 27
2021
|
William P Sheridan Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
71,759
+27.46%
|
$358,795
$5.26 P/Share
|
|
May 24
2021
|
George B Abercrombie Director |
SELL
Open market or private sale
|
Direct |
6,667
-68.97%
|
$86,671
$13.9 P/Share
|
|
May 24
2021
|
George B Abercrombie Director |
BUY
Exercise of conversion of derivative security
|
Direct |
6,667
+40.82%
|
$13,334
$2.63 P/Share
|
|
May 12
2021
|
Alane P Barnes Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
35,852
+19.7%
|
$143,408
$4.73 P/Share
|
|
May 11
2021
|
Alane P Barnes Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
102,780
-48.24%
|
$1,233,360
$12.04 P/Share
|
|
May 11
2021
|
Alane P Barnes Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
102,780
+14.75%
|
$308,340
$3.87 P/Share
|
|
May 10
2021
|
George B Abercrombie Director |
SELL
Open market or private sale
|
Direct |
7,000
-70.0%
|
$84,000
$12.7 P/Share
|
|
Mar 31
2021
|
Helen M. Thackray Chief R&D Officer |
BUY
Grant, award, or other acquisition
|
Direct |
100,000
+50.0%
|
-
|
|
Mar 18
2021
|
Michael L Jones Exec. Director, Finance - PAO |
BUY
Exercise of conversion of derivative security
|
Direct |
4,500
+45.69%
|
$13,500
$3.51 P/Share
|
|
Feb 26
2021
|
Steve Aselage Director |
BUY
Grant, award, or other acquisition
|
Direct |
927
+2.86%
|
$9,270
$10.78 P/Share
|
|
Feb 26
2021
|
Theresa Heggie Director |
BUY
Grant, award, or other acquisition
|
Direct |
463
+3.24%
|
$4,630
$10.78 P/Share
|
|
Feb 26
2021
|
Nancy J Hutson Director |
BUY
Grant, award, or other acquisition
|
Direct |
463
+0.71%
|
$4,630
$10.78 P/Share
|
|
Feb 26
2021
|
Robert Alexander Ingram Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,739
+2.27%
|
$17,390
$10.78 P/Share
|
|
Feb 22
2021
|
William P Sheridan Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
41,250
-78.24%
|
$453,750
$11.57 P/Share
|
|
Feb 22
2021
|
William P Sheridan Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
41,250
+43.89%
|
$165,000
$4.15 P/Share
|
|
Feb 19
2021
|
Yarlagadda S Babu Chief Discovery Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
22,431
-10.91%
|
$246,741
$11.53 P/Share
|
|
Feb 19
2021
|
Yarlagadda S Babu Chief Discovery Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
50,000
+19.56%
|
$200,000
$4.15 P/Share
|
|
Dec 15
2020
|
Jon P Stonehouse President & CEO |
SELL
Open market or private sale
|
Direct |
134,278
-14.62%
|
$1,074,224
$8.32 P/Share
|
|
Dec 15
2020
|
Jon P Stonehouse President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
134,278
+12.76%
|
$537,112
$4.15 P/Share
|
|
Dec 11
2020
|
Alane P Barnes Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
13,741
-11.28%
|
$96,187
$7.96 P/Share
|
|
Dec 11
2020
|
Alane P Barnes Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
13,741
+10.14%
|
$54,964
$4.15 P/Share
|
|
Dec 04
2020
|
Alane P Barnes Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
13,741
-11.28%
|
$82,446
$6.23 P/Share
|